FY2026 Earnings Estimate for IPSEN Issued By HC Wainwright

IPSEN (OTCMKTS:IPSEY) – Stock analysts at HC Wainwright lifted their FY2026 earnings estimates for IPSEN in a research report issued on Wednesday, November 11th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $3.59 for the year, up from their previous forecast of $3.36. The consensus estimate for IPSEN’s current full-year earnings is $3.82 per share. HC Wainwright also issued estimates for IPSEN’s FY2027 earnings at $4.05 EPS.

IPSEY has been the topic of a number of other research reports. Barclays upgraded shares of IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th. Jefferies Financial Group downgraded IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, IPSEN presently has an average rating of “Hold”.

IPSEN Price Performance

Shares of OTCMKTS:IPSEY opened at $46.72 on Thursday. IPSEN has a 52-week low of $34.34 and a 52-week high of $51.10. The stock has a 50 day moving average price of $43.37 and a 200-day moving average price of $45.43.

IPSEN Company Profile

IPSEN is a global biopharmaceutical company headquartered in France. Founded in 1929, it develops and commercializes medicines focused on oncology, rare diseases and neuroscience. Its portfolio includes treatments such as Somatuline for certain neuroendocrine tumors and acromegaly, Dysport for several neurological and aesthetic uses, and Cabometyx for certain cancers. The company also conducts research and development to advance medicines across its therapeutic areas. IPSEN serves patients and healthcare professionals in countries around the world through its international commercial operations and partnerships.